As of June 30, 2025, NRx Pharmaceuticals (NRXP) had approximately $2.9 million in cash and cash equivalents. The Company believes that its current cash position will support operations into 2026 and provide sufficient capital to reach expected regulatory inflection points.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRXP:
- NRX Pharmaceuticals Gains FDA Fast Track for NRX-100
- NRx Pharmaceuticals Delays Q2 2025 Report Filing
- Psychedelic: atai Life Sciences, Cybin report earnings results
- Is NRXP a Buy, Before Earnings?
- NRx Pharmaceuticals (NASDAQ: NRXP) Receives FDA Fast Track Designation for NRX-100 in Treating Suicidal Ideation in Depression